Want To Promote Off-Label? Pick Your Battlefield

US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the FDA's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.